Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
November 11, 2014
RegMed found little impetus to move in one direction or the other
November 5, 2014
Wednesday’s RegMed rhythms, who is helping drive DOWN share pricing - it’s the companies THEMSELVES!
October 29, 2014
Wednesday’s RegMed rhythms – “our” universe as a tennis ball!
October 29, 2014
Cesca (KOOL) begins search for new CEO, transition or factionalism of a “squeeze-out”?
October 28, 2014
RegMed‘s steady daily increases
October 28, 2014
Cesca shareholders file Schedule 13D with SEC
October 24, 2014
RegMed: 4 out of 5 for the week is not too shabby
October 21, 2014
Tuesday’s RegMed rhythms – Transparency needs to be more transcendent!
October 17, 2014
RegMed: What a week - re-issued!
October 16, 2014
Regenerative Medicine Earnings Scorecard - Q3/2014
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.